替尼泊苷加司莫司汀治疗脑转移瘤的临床对照试验  

The Clinical Control Study on the Effect of Teniposide plus Semusfine on Metastatic Brain Tumors

作　　者：冯纪祥[1] 徐崇明[1] 任庆荣[1] 张九成[1] 

机构地区：[1]湖北省肿瘤医院第二住院部,430079

出　　处：《药物流行病学杂志》2000年第3期120-121,共2页Chinese Journal of Pharmacoepidemiology

摘　　要：目的 :回顾性分析放疗 (R)联合替尼泊苷 +司莫司汀化疗 (C)治疗脑转移瘤的疗效和毒副反应。方法 :1993年 3月～ 1998年 12月间收治放疗加化疗 (R +C)病人 30例 ,与同期收治的单纯放疗 (R) 4 2例进行观察比较。结果 :12个月、 >12个月生存率及局部控制率R +C组分别为 2 6 .7% ,2 3 .3 %和 40 .0 % ,R组分别为 16 .2 % ,2 .4%和 19.0 %。 >12个月生存率及局部控制率两组间具有差异显著性 (P <0 .0 5 )。胃肠道反应、脱发等两组基本相似 ,白细胞下降R +C组为 90 .0 % ,其中Ⅲ度占 33.3 % ,R组为 73.8% ,无Ⅲ度及Ⅳ度。结论 :R +C组疗效优于R组 ,但骨髓抑制亦较明显。To study the toxicity and side effect of teniposide (VM-26) plus semustine (MeCCNU), combined with radiotherapy, in the patients with metastatic brain tumor, from March 1993, to Dec. 1998, 30 patients were treated with radiotherapy and combined chemotherapy (VM-26 plus MeCCNU) (R+C group). The results were compared with those of patients receiving radiotherapy along (R group) at same time in our hospital. The 12 and over 12 month survival rates and local control rate were 26.7%, 23.3% and 40% in R+C group and they were 16.2%, 2.4% and 19% in R group, respectively. There were significant differences in over 12-month survival and local control rate ( P<0.05 ). The side effects such as gastrointestinal reactions and hair loss were similar. The WBC reduction was 90% in R+C group, with Ⅲ degree amounting to 33.3% and it was 73.8% in R group. No grade Ⅲ and Ⅳ patients were noted. The radiotherapy and combined chemotherapy (VM-26 plus MeCCNU) was superior to radiotherapy alone but its bone marrow depression was also stronger.

关 键 词：替尼泊苷 司莫司汀 脑转移瘤 对照试验 治疗 

分 类 号：R739.410.5[医药卫生—肿瘤]